Goserelin Plus Tamoxifen Versus Tamoxifen Alone, in Pre-Menopausal or Peri-Menopausal Patients with Hormone Receptor-Positive Early-Stage Breast Cancer: A Randomised Controlled Trial in China

H. J. Yang,X. F. Yu,X. Y. Zong,D. B. Chen,X. W. Ding,Y. Yu,D. H. Zou,X. M. He,W. L. Feng,J. Chen,W. J. Mo,C. Wang
DOI: https://doi.org/10.1016/j.ejca.2016.03.032
IF: 10.002
2016-01-01
European Journal of Cancer
Abstract:Background: Goserelin has been used in pre-menopausal or peri-menopausal patients with hormone receptor-positive (HR+) breast cancer, but few data of Chinese population have been published. We aimed to investigate the effect of goserelin plus tamoxifen (TAM) versus TAM alone on disease-free survival (DFS) and overall survival (OS) in pre-menopausal or peri-menopausal patients with HR+ early-stage breast cancer in China (NCT00827307).
What problem does this paper attempt to address?